ORSF (Otvorený register slovenských firiem) je nezávislý open-data projekt agregujúci 14 oficiálnych slovenských registrov (RPO, ORSR, RÚZ, FS DPH a ďalšie) do jedného REST API a MCP servera. Pre AI agentov, novinárov, compliance a due diligence.

How is ORSF different from ORSR?

ORSR (Obchodný register SR, orsr.sk) is the official Ministry of Justice registry — no public REST API. ORSF (orsf.sk) is an independent open project that uses ORSR as ONE of 14 sources, adding REST API, MCP server, CLI and bulk export.

Yes, public business data is free under CC-BY 4.0. The REST API at https://api.orsf.sk/v1 is publicly accessible. Personal data (sole traders, full director details) requires authentication per GDPR Art. 5(1)(c).

How do AI agents access ORSF?

AI agents can use either the public REST API (https://api.orsf.sk/v1, OpenAPI spec at /v1/openapi.json) or the MCP server (@orsf/mcp-server) for direct integration with Claude Desktop and other MCP-compatible clients.

Nemocnica AGEL Komárno s.r.o.

aktívna

Mederčská 39, 945 05, Komárno

under §4b, registered 01/04/2018

spoločnosť s ručením obmedzenýmVAT registered

Revenue (2025)49,1 mil. €

10,3 %vs 2024

Profit (2025)230 tis. €

93,8 %vs 2024

Equity (2025)630 tis. €

84,5 %vs 2024

Debt ratio (2025)99 %

10,5 %Highvs 2024

ROE (2025)36.6 %

59,8 %Excellentvs 2024

Revenue growth

Revenue grew 10 % year over year.

Stable financial position

The company is financed mainly by equity and has low leverage.

Score 45/100

Stabilná pozícia s niekoľkými silnými stránkami.

Summary

Firma dosahuje významné tržby (49,1 mil. €), vlastné imanie tvorí len malú časť majetku.

Funding risklow capital adequacy 1 %

High leverageexternal sources are 99 % of assets

Low marginnet margin only 0.5 %

Basic information

Legal form: spoločnosť s ručením obmedzeným
Founded: 7. 4. 2017
Address: Mederčská 39, 945 05, Komárno

Revenue and profit trend (5 years)

Revenue Net profit

Key indicators (2025)Show all indicators →

EBITDA margin16,6 %
ROA (return on assets)0,5 %
ROE (return on equity)36,6 %
Debt ratio99 %
Capital ratio1,4 %

Financial health

Firma dosahuje významné tržby (49,1 mil. €), vlastné imanie tvorí len malú časť majetku.

45/ 100Stable

Profitability6 / 20

Academic basisDuPont identity (Brown 1914) + Altman X3 inspiration (Altman 1968).

FormulaBody z Net Margin = NI / Revenue × 100; bonus za zlepšenie YoY.

Thresholds

> 15 % marža → 20 b.
10–15 % → 17 b.
5–10 % → 13 b.
2–5 % → 9 b.
0–2 % → 6 b.
< 0 % → 0–4 b. (úľava ak sa zlepšuje)

Input values

netMargin: 0.469
netIncome: 230 346
revenue: 49 145 043
prevNetIncome: 3 686 812

Solvency1 / 20

Academic basisAltman X4-inspired (Book Equity / Total Liabilities), Altman 1968.

FormulaBody z Equity Ratio = Equity / TA × 100.

Thresholds

> 50 % → 20 b. (silný kapitál)
35–50 % → 16 b.
20–35 % → 12 b.
10–20 % → 7 b.
3–10 % → 3 b.
< 3 % → 1 b.
< 0 → 0 b. (záporné imanie)

Input values

equityRatio: 1.36
equity: 629 526
assets: 46 231 269

Leverage1 / 20

Academic basisStandard banking debt ratio, Basel III intuícia.

FormulaBody z Debt Ratio = (TA − Equity) / TA × 100.

Thresholds

< 30 % → 20 b. (nízka páka)
30–50 % → 16 b.
50–65 % → 12 b.
65–80 % → 7 b.
80–92 % → 3 b.
> 92 % → 1 b.

Input values

debtRatio: 98.64
equity: 629 526
assets: 46 231 269

Growth20 / 20

Academic basisPiotroski F-Score directional momentum (Piotroski 2000), criteria 1, 3.

FormulaBody z Revenue CAGR (3+ rokov) alebo YoY fallback.

Thresholds

CAGR > 15 % → 20 b.
7–15 % → 17 b.
2–7 % → 13 b.
−3 až 2 % → 10 b.
−10 až −3 % → 6 b.
< −10 % → 2 b.

Input values

revenueCAGR: 219.38
revenueYoY: 10.34
validHistoryYears: 9.00

Efficiency17 / 20

Academic basisDuPont Asset Turnover (Brown 1914) + Altman X5 (EBITDA/Revenue proxy).

FormulaBody z EBITDA Margin = EBITDA / Revenue × 100; fallback z Net Margin × 1.3.

Thresholds

EBITDA marža > 20 % → 20 b.
12–20 % → 17 b.
6–12 % → 12 b.
2–6 % → 7 b.
0–2 % → 4 b.
< 0 % → 1 b.

Input values

ebitdaMargin: 16.62
netMargin: 0.469
ebitda: 8 166 429
revenue: 49 145 043

Altman Z''-Score1.82Grey zone

Bankruptcy prediction (modified for service / private firms)

X1 — Working capital / Assets	weight	contribution	—
X1 — Working capital / Assets	6.56	0.03	approximated
X2 — Retained earnings / Assets	3.26	0.76	approximated
X3 — EBIT / Assets	6.72	1.01	approximated
X4 — Equity / Liabilities	1.05	0.01	exact

Altman, E. I. (1995). Corporate Financial Distress Diagnosis. Z'' modifikovaný pre service / private / EM firmy. Thresholds: < 1.1 distress · 1.1–2.6 grey · > 2.6 safe.

Piotroski F-Score1 / 6weak

Fundamental momentum (modified 6/9)

ROA pozitívnaROA = 0.50 %
pass
ΔROA — ziskovosť rastieAktuálne ROA 0.50 % vs. predchádzajúce 9.80 %.
fail
Zadlženosť klesáZadlženosť 98.64 % vs. predchádzajúce 89.24 %.
fail
Obrat aktív rastieObrat aktív 1.06× vs. predchádzajúce 1.18×.
fail
Marža rastie (proxy: čistá marža)Aktuálna marža 0.47 % vs. predchádzajúca 8.28 %.
fail
Kapitálová primeranosť rastieAktuálna 1.36 % vs. predchádzajúca 10.76 %.
fail

Original criteria not covered:

#2 CFO > 0 — chýba výkaz peňažných tokov
#4 CFO > NI (manipulation check) — chýba výkaz peňažných tokov
#6 ΔCurrent Ratio > 0 — chýba rozdelenie aktív na obežné/dlhodobé

Piotroski, J. D. (2000). Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Modified verzia (6/9) — chýbajú kritériá závislé od cash flow výkazu a current/non-current splitu.

Data caveats

X1 (Working Capital / Total Assets) je aproximované ako 0.3 × Equity Ratio. RÚZ neposkytuje rozdelenie aktív na obežné/dlhodobé.
X2 (Retained Earnings / Total Assets) je aproximované kumulatívnym čistým ziskom za 9 rokov / Total Assets. RÚZ neposkytuje rozpis vlastného imania na základné a nerozdelený zisk.
X3 (EBIT / Total Assets) je aproximované ako EBITDA × 0.85 / TA. RÚZ neposkytuje samostatnú hodnotu odpisov.

What the data shows

Positive
Tržby medziročne stúpli o 10 % na 49.1 mil. € — stabilný organický rast.
Info
Čistá marža len 0.5 % — firma je zisková, ale s nízkou rezervou. Každý pokles tržieb môže viesť k strate.
Warning
Kapitálová primeranosť len 1 % — firma je výrazne financovaná z cudzích zdrojov. Vysoká finančná páka zvyšuje riziko.

Financial overview (2025)

Item	2025	2024	Change
Revenue	49,1 mil. €	44,5 mil. €	+10,3 %
EBITDA	8,2 mil. €	11,3 mil. €	−28,0 %
Operating profit (EBIT)	7,3 mil. €	10,2 mil. €	−28,0 %
Net profit	230 tis. €	3,7 mil. €	−93,8 %
Total assets	46,2 mil. €	37,6 mil. €	+22,9 %
Equity	630 tis. €	4,0 mil. €	−84,5 %

Show P&L statement and balance sheet →

Relationships

6 peoplein directors / officers

connection graphvia people 2°/3°

Show all relationships →

Latest events

7. 4. 2017Company founded
31. 12. 2025Financial statements published for 2025
31. 12. 2025All-time high revenue

Show all events →

Financial ratios

2025

EBITDA marginEBITDA / revenue

16.6 %Excellent

Net marginnet profit / revenue

0.5 %Weak

ROAnet profit / total assets

0.5 %Good

ROEnet profit / equity

36.6 %Excellent

Debt ratioexternal sources / assets

98.6 %High

Capital ratioequity / assets

1.4 %Weak

Revenue and profit · 9 years

Assets and equity

Funding structure

2025 · share of own vs. external sources

Equity1.4%
External sources98.6%

Total assets46,2 mil. €

Equity630 tis. €

External sources45,6 mil. €

Financial leverage72.44×

Filings by year

RÚZ · 9 filings

Year	Type	Revenue	Assets	Equity	EBITDA	Net profit	Currency
2025latest	Riadna	49,1 mil. €	46,2 mil. €	630 tis. €	8,2 mil. €	230 tis. €	EUR
2024	Riadna	44,5 mil. €	37,6 mil. €	4,0 mil. €	11,3 mil. €	3,7 mil. €	EUR
2023	Riadna	37,8 mil. €	31,8 mil. €	4,2 mil. €	8,1 mil. €	1,8 mil. €	EUR
2022	Riadna	28,0 mil. €	29,3 mil. €	4,9 mil. €	5,8 mil. €	1,1 mil. €	EUR
2021	Riadna	26,7 mil. €	20,3 mil. €	3,8 mil. €	7,0 mil. €	2,0 mil. €	EUR
2020	Riadna	23,8 mil. €	15,1 mil. €	2,3 mil. €	5,4 mil. €	1,3 mil. €	EUR
2019	Riadna	21,5 mil. €	10,4 mil. €	977 tis. €	4,0 mil. €	419 tis. €	EUR
2018	Riadna	13,3 mil. €	7,3 mil. €	558 tis. €	2,3 mil. €	200 tis. €	EUR
2017	Riadna	5 tis. €	110 tis. €	58 tis. €	5 tis. €	3 tis. €	EUR

Useful services

X1 — Working capital / Assets

weight

contribution

—

X1 — Working capital / Assets

6.56

0.03

approximated

X2 — Retained earnings / Assets

3.26

0.76

approximated

X3 — EBIT / Assets

6.72

1.01

approximated

X4 — Equity / Liabilities

1.05

0.01

exact

Item

2025

2024

Change

Revenue

49,1 mil. €

44,5 mil. €

+10,3 %

EBITDA

8,2 mil. €

11,3 mil. €

−28,0 %

Operating profit (EBIT)

7,3 mil. €

10,2 mil. €

−28,0 %

Net profit

230 tis. €

3,7 mil. €

−93,8 %

Total assets

46,2 mil. €

37,6 mil. €

+22,9 %

Equity

630 tis. €

4,0 mil. €

−84,5 %

Nemocnica AGEL Komárno s.r.o.

Revenue growth

Stable financial position

Score 45/100

Financial health

Financial ratios

Funding structure

Filings by year

History and changes

Financial statements

Business activities

Sources & traceability

Nemocnica AGEL Komárno s.r.o.

Revenue growth

Stable financial position

Score 45/100

Financial health

Financial ratios

Funding structure

Filings by year

History and changes

Financial statements

Business activities

Sources & traceability